NCT06370949View on ClinicalTrials.gov

The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block

Not yet recruitingOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

November 30, 2024

Conditions
Colorectal CancerColorectal Neoplasms
Interventions
DRUG

Bupivacain

Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain

DRUG

bupivacain+dexmedetomidine

Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine

Trial Locations (1)

06110

Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital, Ankara

All Listed Sponsors
lead

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

OTHER

NCT06370949 - The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block | Biotech Hunter | Biotech Hunter